NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,472.97 +265.84 (+1.46%) CRUDE OIL
79.08 +0.13 (+0.16%) GOLD FUTURES
2,310.90 +1.30 (+0.06%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,448.45 +1,697.85 (+3.71%)
DiaMedica Therapeutics Inc. (DMAC)
| Previous close | 2.5900 |
| Open | 2.6000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.5752 - 2.6300 |
| 52-week range | 1.5800 - 4.7500 |
| Volume | |
| Avg. volume | 37,572 |
| Market cap | 99.83M |
| Beta (5Y monthly) | 1.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6000 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
- Business Wire
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
MINNEAPOLIS, May 02, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close on Wednesday, May 8th. DiaMedica will host a live conference call on Thursday, May 9th at 7:00 AM Central Time to provide a business update and discuss financial results.
Simply Wall St.Bullish DiaMedica Therapeutics Insiders Loaded Up On US$15.7m Of Stock
Multiple insiders secured a larger position in DiaMedica Therapeutics Inc. ( NASDAQ:DMAC ) shares over the last 12...
ZacksDiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
